Profit From The Race For A Zika Vaccine
Investment U | Aug 09, 2016 02:55AM ET
The Zika virus is back in the headlines. And it’s becoming harder and harder to ignore... especially because a viable Zika vaccine hasn’t reached the market yet.
At last count, 14 Zika cases have been reported in Florida. It’s not the first time U.S. citizens have contracted the virus, but it is the first time it’s been contracted from local mosquitos.
The Florida government is working to quarantine the site of the outbreak. But at this point, it’s likely these Zika-carrying mosquitos are here to stay.
The media is delivering round-the-clock coverage of “Zikamania.” And believe it or not, there is an upside...
One that could generate some big short-term gains for your portfolio.
We’re talking about investing in an indispensable $24 billion industry.
As much as people hate getting shots, the risk of serious illness has a funny way of propelling us toward the nearest doctor’s office.
Historically, vaccine manufacturers perform well during health crises. Take, for example, the meningitis outbreak of 2015.
Sanofi (PA:SASY), the company behind the meningitis vaccine Menactra, started the year with a $44.55 share price.
By August, the stock was worth $53.48.
A 20% jump.
Now to combat Zika, two companies have joined forces...
Inovio Pharmaceuticals Inc (NASDAQ:INO) and GeneOne Life Science Inc (KS:011000) just announced that their Zika vaccine has been approved for a Phase 1 human trial.
Year to date, Inovio shares are up 55%. And the stock should continue to gain with every piece of positive news.
Sanofi is also working to develop a Zika vaccine. And it has got one heck of a research partner...
The U.S. Army.
The beauty of this partnership is that it will legitimize Sanofi’s vaccine to a global audience. After all, the success of a vaccine depends on the approval of various governments.
Get The News You Want
For example, if Brazil approves Sanofi’s vaccine, that will expand the company’s client base by about 1.5 million people.
The World Health Organization estimates that 3 to 4 million Zika infections could appear in the Americas this year. The pressure is on to develop a working vaccine.
Whether it’s Inovio or Sanofi that gets approval first, both companies - and their shareholders - stand to book some major short-term gains.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.